EISAI CO LTD (EII.SG) (EII STU) stock market data APIs
€26.3142
0(0%)
as of October 2, 2026
Try our APIs with
free plan!
EISAI CO LTD (EII.SG) Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for EII.SG.
Prev. Close
26.3142
Open
26.3156
High
26.5861
Low
26.2113
52 wk Range
19.3114-27.7353
Market Cap
15 022 M
EPS
39.18
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get EISAI CO LTD (EII.SG) data using free add-ons & libraries
Get EISAI CO LTD (EII.SG) Fundamental Data
EISAI CO LTD (EII.SG) Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-07
- EPS/Forecast: 32.09
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
EISAI CO LTD (EII.SG) News
New
EISAI TO BEGIN ENROLLING STUDY IN PATIENTS WITH NARCOLEPSY
NUTLEY, N.J., July 8, 2024 /PRNewswire/ -- Eisai Inc. announced today that screening for Study E2086-A001-101 (Study 101) to assess the efficacy, safety and tolerability of E2086, a novel selective o...
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
TOKYO and CAMBRIDGE, Mass., May 14, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachuset...
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
TOKYO and CAMBRIDGE, Mass., March 31, 2024 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachuse...
Biogen Quits Controversial Alzheimer’s Drug Aduhelm
The company says it will continue to advance another drug, Leqembi, and accelerate the development of other treatments. Continue reading
Get EISAI CO LTD (EII.SG) fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.